Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...

- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - In the pharmaceutical industry, the ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help ...

While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and release QC. Cell Shuttles™ and Cell Qs™ will be deployed ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

The "Cell Therapy Processing: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering. The global market for cell therapy processing is estimated to grow from $2.7 ...